|
1
|
Ostrom QT, Gittleman H, Xu J, Kromer C,
Wolinsky Y, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: Primary brain and other central nervous system tumors
diagnosed in the united states in 2009-2013. Neuro Oncol. 18 (suppl
5):v1–v75. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Oronsky B, Reid TR, Oronsky A, Sandhu N
and Knox SJ: A review of newly diagnosed glioblastoma. Front Oncol.
10(574012)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Abbott NJ, Patabendige AA, Dolman DE,
Yusof SR and Begley DJ: Structure and function of the blood-brain
barrier. Neurobiol Dis. 37:13–25. 2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bailey P and Cushing H: A classification
of the tumours of the glioma group on a histogenetic basis, with a
correlated study of prognosis. Medium 8vo. Pp. 175, with 108
illustrations. 1926. Volume 14. Issue 55. J. B. Lippincott Company.
21s. net, British Journal of Surgery, Philadelphia, London, and
Montreal, pp554-555 1927.
|
|
5
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
Classification of Tumors of the Central Nervous System: A summary.
Acta Neuropathol. 131:803–820. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastomain a randomised phase III study: 5-year analysis of the
EORTC/NCIC trial. Lancet Oncol. 10:459–466. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Louis DN, Perry A, Wesseling P, Brat DJ,
Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM,
Reifenberger G, et al: The 2021 WHO classification of tumors of the
central nervous system: A summary. Neuro Oncol. 23:1231–1251.
2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Han S, Liu Y, Cai SJ, Qian M, Ding J,
Larion M, Gilbert MR and Yang C: IDH mutation in glioma: Molecular
mechanisms and potential therapeutic targets. Br J Cancer.
122:1580–1589. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Stupp R, Taillandier L, Kanner AA, Kesari
S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink
KL, et al: Maintenance therapy with tumor-treating fields plus
temozolomide vs temozolomide alone for glioblastoma: A Randomized
Clinical Trial. JAMA. 314:2535–2543. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Munoz-Casabella A, Alvi MA, Rahman M,
Burns TC and Brown DA: Laser interstitial thermal therapy for
recurrent glioblastoma: Pooled analyses of available literature.
World Neurosurg. 153:91–97.e1. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Liau LM, Ashkan K, Brem S, Campian JL,
Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, et
al: Association of autologous tumor lysate-loaded dendritic cell
vaccination with extension of survival among patients with newly
diagnosed and recurrent glioblastoma: A phase 3 prospective
externally controlled cohort trial. JAMA Oncol. 9:112–121.
2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Brown CE, Alizadeh D, Starr R, Weng L,
Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J,
Simpson J, et al: Regression of glioblastoma after chimeric antigen
receptor T-cell therapy. N Engl J Med. 375:2561–2569.
2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Manz C, Chivers C, Liu M, Regli SB,
Channgolkar S, Evans CN, Draugelis M, Braun J, Navathe AS, Kumar P,
et al: Prospective validation of a machine learning algorithm to
predict short-term mortality among outpatients with cancer. J Clin
Oncol. 38(15_suppl)2009.
|
|
15
|
Tan AC, Ashley DM, López GY, Malinzak M,
Friedman HS and Khasraw M: Management of glioblastoma: State of the
art and future directions. CA Cancer J Clin. 70:299–312.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Iwamoto FM, Cooper AR, Reiner AS, Nayak L
and Abrey LE: Glioblastoma in the elderly: The memorial
sloan-kettering cancer center experience (1997-2007). Cancer.
115:3758–3766. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sanai N, Polley MY, McDermott MW, Parsa AT
and Berger MS: An extent of resection threshold for newly diagnosed
glioblastomas. J Neurosurg. 115:3–8. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cairncross G, Wang M, Jenkins RB, et al:
Benefit of procarbazine, lomustine, and vincristine in
glioblastoma. J Clin Oncol. 32:294–301. 2014.
|
|
19
|
Keime-Guibert F, Chinot O, Taillandier L,
Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin
P, Bondiau PY, et al: Radiotherapy for glioblastoma in the elderly.
N Engl J Med. 356:1527–1535. 2007.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Grossman SA and Batara JF: Current
management of glioblastoma multiforme. Semin Oncol. 31:635–644.
2004.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Weller M, Roth P, Preusser M, Wick W,
Reardon DA, Platten M and Sampson JH: Vaccine-based
immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol.
13:363–374. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Weller M, Wick W, Aldape K, Brada M,
Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R and
Reifenberger G: Glioblastoma. Nat Rev Dis Primers.
1(15017)2015.
|
|
23
|
Karsy M, Arslan E and Moy F: Current
progress on understanding microRNAs in glioblastoma multiforme.
Genes Cancer. 3:3–15. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Woroniecka K, Chongsathidkiet P, Rhodin K,
Kemeny H, Dechant C, Farber SH, Elsamadicy AA, Cui X, Koyama S,
Jackson C, et al: T-cell exhaustion signatures vary with tumor type
and are severe in glioblastoma. Clin Cancer Res. 24:4175–4186.
2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Reardon DA, Brandes AA, Omuro A,
Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr
O, et al: Effect of nivolumab vs bevacizumab in patients with
recurrent glioblastoma: the CheckMate 143 phase 3 Randomized
clinical trial. JAMA Oncol. 6:1003–1010. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Müller S, Kohanbash G, Liu SJ, Alvarado B,
Carrera D, Bhaduri A, Watchmaker PB, Yagnik G, Di Lullo E,
Malatesta M, et al: Single-cell profiling of human gliomas reveals
macrophage ontogeny as a basis for regional differences in
macrophage activation in the tumor microenvironment. Genome Biol.
18(234)2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Mrugala MM, Engelhard HH, Dinh Tran D, Kew
Y, Cavaliere R, Villano JL, Annenelie Bota D, Rudnick J, Love
Sumrall A, Zhu JJ and Butowski N: Clinical experience with
NovoTTF-100A TMsystem for glioblastoma: The Patient
Registry Dataset (PRiDe). Semin Oncol. 41 (Suppl 6):S4–S13.
2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Liau LM, Ashkan K, Tran DD, Campian JL,
Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, et
al: First results on survival from phase 3 chinical trial of an
autologous dendritic cell vaccine in newly diagnosed glioblastoma.
J Transl Med. 16(142)2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wong CE, Chang Y, Chen PW, Huang YT, Chang
YC, Chiang CH, Wang LC, Lee PH, Huang CC, Hsu HJ and Lee JS:
Dendritic cell vaccine for glioblastoma: An updated meta-analysis
and trial sequential analysis. J Neurooncol. 170:253–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sampson JH, Maus MV and April CB:
Immunotherapy for brain tumors. J Clin Oncol. 35:2450–2456.
2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Friedman HS, Prados MD, Wen PY, Mikkelsen
T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen
R, et al: Bevacizumab alone and in combination with irinotecan in
recurrent glioblastoma. J Clin Oncol 2009. 27:4733–4740.
2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chinot OL, Wick W, Mason W, Henriksson R,
Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea
D, et al: Bevacizumab plus radiotherapy-temozolomide for newly
diagnosed glioblastoma. N Engl J Med. 370:709–722. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tsien CI, Pugh SL, Dicker AP, Raizer JJ,
Matuszak MM, Lallana EC, Huang J, Algan O, Deb N, Portelance L, et
al: NRG Oncology/RTOG1205: A randomized phase II trial of
concurrent bevacizumab and reirradiation versus bevacizumab alone
as treatment for recurrent glioblastoma. J Clin Oncol.
41:1285–1295. 2023.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chen W, Wang Y, Zhao B, Liu P, Liu L, Wang
Y and Ma W: Optimal therapies for recurrent glioblastoma: A
bayesian network meta-analysis. Front Oncol.
11(641878)2021.PubMed/NCBI View Article : Google Scholar
|
